Company intelligence / Profile preview
Verra Therapeutics
Near Ithaca / Ithaca area, New York, United Statesverratherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Verra Therapeutics develops novel small protein drugs that inhibit disease-driving regulatory proteases. Their lead candidate, VTH245, has shown efficacy in animal models for reducing mucus overproduction and lung damage in COPD. The company’s approach adapts nature’s evolved inhibitor sequences for each target. VTH245 demonstrates favorable pharmacokinetics, compatibility with subcutaneous/inhaled administration, good tolerability in toxicity studies, and potential suitability for chronic use.
- Therapeutic areas
- PulmonologyCardiovascularImmunology
- Modalities
- Small proteinsProtein inhibitors
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Verra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verra Therapeutics.